Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Danshu is a Traditional Chinese Medicine (TCM) therapeutic, typically formulated as a capsule, containing peppermint oil (Mentha haplocalyx oil) as its primary active ingredient. It is widely utilized in China for the management of biliary tract disorders, including chronic cholecystitis, cholelithiasis (gallstones), and the prevention of stone recurrence following endoscopic retrograde cholangiopancreatography (ERCP). The drug's efficacy is largely attributed to L-menthol, which acts as a calcium channel antagonist to relax biliary smooth muscle and the sphincter of Oddi, thereby facilitating bile flow and the passage of stones. Additionally, Danshu possesses choleretic properties, increasing the secretion and flow of bile to reduce biliary stasis and prevent stone formation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Danshu.